NCT02548806View on ClinicalTrials.gov

Phase 1 PK, Bioavailability, Safety Study of Clonidine MBT w Catapres in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

April 30, 2016

Conditions
Healthy
Interventions
DRUG

Clonidine MBT 50µg

Clonidine MBT 50µg, single dose

DRUG

Clonidine MBT 100µg

Clonidine MBT 100µg, single dose

DRUG

Catapres 100μg

Catapres tablet 100μg, single dose

Trial Locations (1)

CF48 4DR

Simbec Research Limited, Merthyr Tydfil

Sponsors
All Listed Sponsors
collaborator

Simbec Research

INDUSTRY

lead

Valerio Therapeutics

INDUSTRY

NCT02548806 - Phase 1 PK, Bioavailability, Safety Study of Clonidine MBT w Catapres in Healthy Volunteers | Biotech Hunter | Biotech Hunter